Tilogotamab is a monoclonal antibody targeting TNFRSF10B (TRAILR2/CD262), a receptor involved in the induction of apoptosis in cancer cells. Its primary application lies in oncology, particularly in the development of targeted cancer therapies. By binding to TRAILR2, tilogotamab activates the extrinsic apoptotic pathway, selectively triggering cell death in tumor cells that express the receptor, while sparing normal healthy cells. This antibody has shown promise in clinical studies for treating solid tumors and hematologic malignancies, including certain types of lung cancer, colorectal cancer, and non-Hodgkin lymphoma. It is being investigated both as a monotherapy and in combination with other anticancer agents, such as immune checkpoint inhibitors, to enhance antitumor activity. Due to its mechanism of action, tilogotamab represents a potential strategy to overcome resistance to conventional chemotherapy and radiation. Its development supports the growing field of pro-apoptotic receptor-targeted therapies, aiming to improve treatment specificity and reduce off-target toxicity in cancer patients.